Beneficial Effects of Thiazolidinediones on Diabetic Nephropathy in OLETF Rats

다국어 초록 (Multilingual Abstract)

Purpose: Diabetic nephropathy is the most serious of complications in diabetes mellitus. Thiazolidinedione (TZD) is thought to ameliorate diabetic nephropathy; however, the mechanism underlying this effect has not been elucidated. We hypothesized that the vascular endothelial growth factor (VEGF) participates in the pathogenesis of diabetic nephropathy and that TZD may be beneficial for the treatment of diabetic nephropathy because of the effect it has on VEGF. Materials and Methods: 23 Otsuka- Long-Evans-Tokushima-Fatty (OLETF) rats and eight control Long-Evans-Tokushima-Otsuka (LETO) rats were divided into the following four groups: LETO group, control OLETF group, pioglitazone treated group (10mg/ kg/day), and rosiglitazone treated group (3mg/kg/day). Results: A progressive increase in urinary protein excretion was observed in the diabetic rats. Glomerular VEGF expression in the control OLETF rats was significantly higher than in the control LETO rats. However, there was a significant reduction in both the glomerular VEGF expression and the VEGF mRNA levels after treatment with pioglitazone and rosiglitazone. The twenty-four hour urine protein levels were significantly decreased in both groups of the treated OLETF rats. Conclusion: These results suggest that TZD may have beneficial effects on diabetic nephropathy by reducing the VEGF expression.

참고문헌 (Reference)

1 "Vascular endothelial growth factor/ vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium" 95 : 1030-1037, 1997

2 "Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats" 183 : 183-194, 2004

3 "Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells" 557-62,

4 "Thiazolidinediones" 26 : 553-573, 1997

5 "Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin- sensitizing action in diabetic rats" 49 : 1022-1032, 2000

6 "The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms" 29 : 153-163, 1997

7 "The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes" Nyengaard JR diabetologia1993;36189-94

8 "The extracellular matrix in diabetic nephropathy" 736-44,

9 "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195" 42 : 579-588, 1999

10 "Rosiglitazone reduces urinary albumin excretion in type II diabetes" 17 : 7-12, 2003

11 "Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients" 54 : 2206-2211, 2005

12 "Role of vascular endothelial growth factor in the regulation of angiogenesis" 56 : 794-814, 1999

13 "Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione" 317 : 24-29, 2004

14 "Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria" 50 : 1193-1196, 2001

15 "Metabolic and additional vascular effects of thiazolidinediones" 62 : 1463-1480, 2002

16 "Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes" 48 : 2229-2239, 1999

17 "Expression of vascular permeability factor (VPF/ VEGF) is altered in many glomerular diseases" 7 : 661-666, 1996

18 "Expression of vascular endothelial growth factor and its receptors in rats with protein overload nephrosis" 13 : 2519-2528, 1998

19 "Evaluation of an automated pyrogallol red-molybdate method for the measurement of urinary protein in rats" 34 : 569-571, 1996

20 "Estimation of glomerular volume a comparison of four methods" 1085-9,

21 "Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria" 18 : 308-313, 2001

22 "Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy" 21 : 2135-2139, 1998

23 "Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells" 53 : 312-319, 1998

24 "Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation" 323 : 782-788, 2004

25 "Clinical practice: nephropathy in patients with type 2 diabetes" 346 : 1145-1151, 2002

26 "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats" 272 : E989-996, 1997

27 "Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes" 12 : 993-1000, 2001

28 "Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy" 290 : F600-F605, 2006

29 "Angotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes" 36 : 65-70, 2002

30 "Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody" 51 : 3090-3094, 2002

31 "Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone" 278 : 704-711, 2000